These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17692029)

  • 1. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development.
    Gill AL; Verdonk M; Boyle RG; Taylor R
    Curr Top Med Chem; 2007; 7(14):1408-22. PubMed ID: 17692029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of physiochemical property profiles of development and marketed oral drugs.
    Wenlock MC; Austin RP; Barton P; Davis AM; Leeson PD
    J Med Chem; 2003 Mar; 46(7):1250-6. PubMed ID: 12646035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular inflation, attrition and the rule of five.
    Leeson PD
    Adv Drug Deliv Rev; 2016 Jun; 101():22-33. PubMed ID: 26836397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
    Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
    J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-related differences in the physical property profiles of oral drugs.
    Leeson PD; Davis AM
    J Med Chem; 2004 Dec; 47(25):6338-48. PubMed ID: 15566303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of synthetic oral drug properties.
    Proudfoot JR
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1087-90. PubMed ID: 15686918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
    Zificsak CA; Theroff JP; Aimone LD; Albom MS; Angeles TS; Brown RA; Galinis D; Grobelny JV; Herbertz T; Husten J; Kocsis LS; LoSardo C; Miknyoczki SJ; Murthy S; Rolon-Steele D; Underiner TL; Wells-Knecht KJ; Worrell CS; Zeigler KS; Dorsey BD
    Bioorg Med Chem Lett; 2011 Jan; 21(2):660-3. PubMed ID: 21190849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
    Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of specific "drug-like property" rules for carboxylate-containing oral drug candidates.
    Böcker A; Bonneau PR; Hucke O; Jakalian A; Edwards PJ
    ChemMedChem; 2010 Dec; 5(12):2102-13. PubMed ID: 20979082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Drug-likeness Rules Apply to Oral Prodrugs?
    Protti ÍF; Rodrigues DR; Fonseca SK; Alves RJ; de Oliveira RB; Maltarollo VG
    ChemMedChem; 2021 May; 16(9):1446-1456. PubMed ID: 33471444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristic physical properties and structural fragments of marketed oral drugs.
    Vieth M; Siegel MG; Higgs RE; Watson IA; Robertson DH; Savin KA; Durst GL; Hipskind PA
    J Med Chem; 2004 Jan; 47(1):224-32. PubMed ID: 14695836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery.
    Whitehurst BC; Bauer MR; Edfeldt F; Gunnarsson A; Margreitter C; Rawlins PB; Storer RI
    J Med Chem; 2023 Jun; 66(11):7594-7604. PubMed ID: 37224440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
    Bussenius J; Anand NK; Blazey CM; Bowles OJ; Bannen LC; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Kim MH; Klein RR; Laird D; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W; Rice KD
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2283-6. PubMed ID: 22342124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs.
    Shultz MD
    J Med Chem; 2019 Feb; 62(4):1701-1714. PubMed ID: 30212196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
    Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
    Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
    Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.